Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Arimoclomol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 14/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arimoclomol SCHEMBL5699254 | 1.00 | HSF1 (0.48) | HSF1ABCB1MAPK1 | |
| Arimoclomol SCHEMBL17607036 | 1.00 | HSF1 (0.48) | HSF1ABCB1MAPK1 | |
| Arimoclomol SCHEMBL196123 | 0.92 | HSF1 (0.54) | HSF1ABCB1 | |
| Arimoclomol SCHEMBL2324741 | 0.92 | HSF1 (0.54) | HSF1ABCB1 | |
| Arimoclomol SCHEMBL25257807 | 0.92 | HSF1 (0.54) | HSF1ABCB1 | |
| Arimoclomol SCHEMBL25258754 | 0.92 | HSF1 (0.54) | HSF1ABCB1 | |
| Arimoclomol SCHEMBL12254223 | 0.92 | HSF1 (0.54) | HSF1ABCB1 | |
| Arimoclomol SCHEMBL12254225 | 0.92 | HSF1 (0.54) | HSF1ABCB1 | |
| Arimoclomol SCHEMBL5699241 | 0.92 | HSF1 (0.54) | HSF1ABCB1 | |
| Arimoclomol SCHEMBL1896428 | 0.92 | HSF1 (0.54) | HSF1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226036-A1 | ARIMOCLOMOL FOR TREATING GAUCHER DISEASE | Zevra Denmark A/S (DK) | 2023-07-20 | — | — | US | claimed |
| EP-4171559-A1 | ARIMOCLOMOL FOR TREATING GAUCHER DISEASE | Zevra Denmark A/S (DK) | 2023-05-03 | — | — | EP | claimed |
| US-20220133707-A1 | ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS | Zevra Denmark A/S (DK) | 2022-05-05 | — | — | US | claimed |
| US-11253505-B2 | Arimoclomol for treating glucocerebrosidase associated disorders | ORPHAZYME A/S (DK) | 2022-02-22 | — | — | US | claimed |
| US-11229633-B2 | Arimoclomol formulation | ORPHAZYME A/S (DK) | 2022-01-25 | — | — | US | claimed |
| WO-2021260120-A1 | ARIMOCLOMOL FOR TREATING GAUCHER DISEASE | ORPHAZYME A/S (DK) | 2021-12-30 | — | — | WO | claimed |
| EP-3922242-A1 | ARIMOCLOMOL FORMULATION | Orphazyme A/S (DK) | 2021-12-15 | — | — | EP | claimed |
| US-20210186949-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | KEMPHARM, INC. | 2021-06-24 | — | — | US | claimed |
| EP-3193840-B1 | ARIMOCLOMOL FORMULATION | ORPHAZYME AS (DK) | 2021-05-19 | — | — | EP | claimed |
| EP-3782624-A1 | ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS | Orphazyme A/S (DK) | 2021-02-24 | — | — | EP | claimed |
| US-20200085812-A1 | HEAT SHOCK PROTEIN INDUCERS AND FRONTOTEMPORAL DISORDERS | KEMPHARM, INC. | 2020-03-19 | — | — | US | claimed |
| US-20190201389-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | Zevra Denmark A/S (DK) | 2019-07-04 | — | — | US | claimed |
| US-20190111041-A1 | ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS | KEMPHARM, INC. | 2019-04-18 | — | — | US | claimed |
| EP-3442530-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | Orphazyme A/S (DK) | 2019-02-20 | — | — | EP | claimed |
| WO-2018215597-A1 | HEAT SHOCK PROTEIN INDUCERS AND FRONTOTEMPORAL DISORDERS | ORPHAZYME A/S (DK) | 2018-11-29 | — | — | WO | claimed |
| WO-2017186919-A1 | ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS | ORPHAZYME APS (DK) | 2017-11-02 | — | — | WO | claimed |
| WO-2017178029-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | ORPHAZYME APS (DK) | 2017-10-19 | — | — | WO | claimed |
| US-20170239232-A1 | ARIMOCLOMOL FORMULATION | Zevra Denmark A/S (DK) | 2017-08-24 | — | — | US | claimed |
| EP-3193840-A1 | ARIMOCLOMOL FORMULATION | Orphazyme APS (DK) | 2017-07-26 | — | — | EP | claimed |
| WO-2016041561-A1 | ARIMOCLOMOL FORMULATION | ORPHAZYME APS (DK) | 2016-03-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226036-A1 | ARIMOCLOMOL FOR TREATING GAUCHER DISEASE | GBA1, GAA, GALC | HSF1 4302/4885ABCB1 2745/4885MAPK1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.